Sunil HealthcareBOM:537253 -5.51%52 EBITDA Margin % is 11.31% as of Mar. 2026, which is 22% below its 10-year median of 14.56. GuruFocus rates BOM:537253 with a GF Score™ of 52/100 and a GF Value™ of ₹71.26 (Fairly Valued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, Sunil Healthcare ranks better than 61.24% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sunil Healthcare's EBITDA for the
three
months ended in Mar. 2026 was ₹22.3 Mil. Sunil Healthcare's Revenue for the
three
months ended in Mar. 2026 was ₹197.2 Mil. Therefore, Sunil Healthcare's EBITDA margin for the quarter that ended in Mar. 2026 was 11.31%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sunil Healthcare EBITDA Margin % Related Terms
Sunil Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sunil Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunil Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunil Healthcare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunil Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sunil Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunil Healthcare (BOM:537253) has a EBITDA Margin % of 11.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunil Healthcare and its competitors. This is 22% below median its historical median of 14.56. Over the past decade, Sunil Healthcare's EBITDA Margin % has ranged from 9.18 to 17.95. According to the industry distribution chart, Sunil Healthcare ranks #369 out of 952 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Sunil Healthcare's EBITDA Margin % too high?
Sunil Healthcare's current EBITDA Margin % of 11.31% is 22% below median its 10-year median of 14.56. Over the past 10 years, this metric has ranged from a low of 9.18 to a high of 17.95. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Sunil Healthcare's value of 11.31% is 9.3% below this industry median. Based on the distribution chart, Sunil Healthcare ranks #369 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sunil Healthcare has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sunil Healthcare's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sunil Healthcare ranks #369 out of 952 companies for EBITDA Margin %. This puts Sunil Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Sunil Healthcare's value of 11.31% is 9.3% below this benchmark. Historically, Sunil Healthcare's own EBITDA Margin % has ranged from 9.18 to 17.95 over the past decade. While the company's 10-year median is 14.56 vs. the industry median of 12.47, Sunil Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunil Healthcare's current EBITDA Margin % of 11.31% is 9.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunil Healthcare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunil Healthcare's current EBITDA Margin % is 11.31%, which is 22% below median its own 10-year median of 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunil Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sunil Healthcare (BOM:537253) is currently considered Fairly Valued. The stock's GF Value™ is ₹71.26, compared to a current price of ₹67.01 — trading 6% below its estimated fair value. The current EBITDA Margin % is 11.31%, which is 22% below median its 10-year median of 14.56 and 9.3% below the Drug Manufacturers industry median of 12.47. Sunil Healthcare's overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunil Healthcare (BOM:537253), the current EBITDA Margin % is 11.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunil Healthcare (BOM:537253) Overvalued in 2026?
Based on GuruFocus' analysis, Sunil Healthcare stock appears to be undervalued.
The current stock price of ₹67.01 is trading 6% below its estimated GF Value™ of ₹71.26.
GuruFocus considers Sunil Healthcare to be Fairly Valued.
Key valuation signals for BOM:537253:
EBITDA Margin %: 11.31% (22% below median its 10-year median of 14.56)
GF Value™: ₹71.26 vs. price of ₹67.01 (6% below fair value)
Industry Position: 9.3% below the Drug Manufacturers median (#369 of 952)
No single metric tells the full story. See the BOM:537253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunil Healthcare Ltd manufactures hard gelatin capsule shells that are used by pharmaceutical and food supplement companies. It operates in a single segment, that is, Empty Capsules. The company manufactures nine different sizes of capsules. Its products include BSE Free Capsules, Pearl Capsules, Liquid Fill Capsules, Stick Free Capsules, and Preservative Free Capsules. The company generates the majority of its revenue from India.
52GF Score
Get the complete analysis for BOM:537253
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:537253 has been successfully added to your 
